Liraglutide: uses, evidence and status

compound file

The answer, first. A once-daily GLP-1 receptor agonist derived from human GLP-1 by Novo Nordisk, marketed since 2010 as Victoza and since 2014 as Saxenda. The strongest evidence is for chronic weight management, graded A — approval or replicated trials. Approved indication.

SCALE: 8.4 kg lost vs 2.8 kg on placebo at 56 weeks, roughly 8% vs 2.6% ¹. 63.2% vs 27.1% lost at least 5% ¹.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 6 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Chronic weight managementSCALE, n=3,731, 56 weeks · superseded by the human recordgrade AApproved indication. SCALE: 8.4 kg lost vs 2.8 kg on placebo at 56 weeks, roughly 8% vs 2.6% ¹. 63.2% vs 27.1% lost at least 5% ¹.

02Type 2 diabetes glycemic controlLEAD program, phase 3 · superseded by the human recordgrade AApproved as Victoza. LEAD-3: HbA1c fell 1.14% on 1.8 mg monotherapy vs 0.51% on glimepiride over 52 weeks ².

03Cardiovascular risk reduction in type 2 diabetesLEADER, n=9,340 · superseded by the human recordgrade AApproved indication. LEADER: major cardiovascular events in 13.0% vs 14.9% on placebo over a median 3.8 years, hazard ratio 0.87 ³. Cardiovascular death 4.7% vs 6.0% ³.

04Obesity in adolescents 12 to 17one RCT, n=251 · superseded by the human recordgrade AApproved since 2020. BMI standard-deviation score fell 0.22 more than placebo at 56 weeks ⁴. 43.3% vs 18.7% cut BMI by at least 5% ⁴. BMI rebounded after discontinuation ⁴.

05Diabetes prevention in prediabetes3-year RCT, n=2,254 · superseded by the human recordgrade BTime to diabetes onset was 2.7 times longer than placebo over 160 weeks, hazard ratio 0.21 ⁵. Well-powered, but not an approved indication.

06NASH resolutionLEAN, n=52 · superseded by the human recordgrade CLEAN phase 2: steatohepatitis resolved in 9 of 23 biopsied vs 2 of 22 on placebo, 39% vs 9% ⁶. Small, and superseded by the newer incretin MASH programs.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetAgonist at the GLP-1 receptor. A fatty-acid chain on the GLP-1 backbone binds albumin, stretching half-life from minutes to about 13 hours ⁹.

2signalGlucose-dependent insulin secretion rises, glucagon falls, gastric emptying slows, hypothalamic appetite signalling is suppressed ⁹.

3effectBody weight fell 8.4 kg vs 2.8 kg at 56 weeks ¹. HbA1c fell 1.14 points as monotherapy ².

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

Parity with the weekly incretins. STEP 8 head-to-head: semaglutide 15.8% vs liraglutide 6.4% lost at 68 weeks, n=338 ⁷.
Results that last after stopping. In the adolescent trial BMI rebounded after withdrawal, rising more than placebo ⁴. Regain is the class pattern.
Type 1 diabetes add-on. ADJUNCT ONE, n=1,398: HbA1c fell 0.2 points, but hypoglycemia and ketosis rose ⁸. Never approved.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeOnce-daily subcutaneous injection in abdomen, thigh or upper arm, any time of day ⁹.

formatPrefilled multi-dose pens as the approved product. Gray-market vials are uncommon for this compound.

published dosesSaxenda label: 0.6 mg daily, raised by 0.6 mg weekly to the 3.0 mg maintenance dose ⁹. Victoza: 0.6 to 1.2 mg daily, optionally 1.8 mg ¹⁰. SCALE dosed 3.0 mg ¹.

human pharmacokineticsPlasma half-life about 13 hours after subcutaneous injection ⁹. Dosing is once daily.

reported conventionsAs reported on GLP-1 forums and r/liraglutide, 2015-2026: mostly prescription pens rather than research vials. The label ladder is followed, with the dose stepped back when nausea bites. Injections are anchored to a daily habit. A thinner reported record than the weekly drugs. Convention, not guidance.

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetEscalation to 3.0 mg takes five weeks on the label ⁹. SCALE measured its 8.4 kg at week 56 ¹. The 3-year extension held near 6% down at week 160 ⁵. As reported: appetite effects arrive within days of a step.

most common reportAs reported: modest appetite quieting, early nausea, and the daily injection itself as the most-cited burden.

adverse effectsSCALE: mild or moderate nausea and diarrhea most frequent ¹. Serious adverse events in 6.2% vs 5.0% on placebo ¹. Adolescents: gastrointestinal events 64.8% vs 36.5%, discontinuation for adverse events 10.4% vs 0 ⁴.

the stop signalLabel: discontinue for suspected pancreatitis ⁹. Contraindicated with personal or family medullary thyroid carcinoma or MEN2 history ⁹. As reported: persistent nausea at a step is the signal to hold or drop.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalFDA-approved as Victoza [2010, diabetes] and Saxenda [2014 for weight, 2020 for adolescents 12-17]. EMA-approved.

FDAApproved and generic products only. Research-market liraglutide is unapproved. The FDA GLP-1 import alert and compounding restrictions apply to this class as a whole.

sport [WADA]Not on the WADA Prohibited List. GLP-1 agonists are not banned in sport.

sold asapproved medicine

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is Liraglutide used for?

Four approved lanes: type 2 diabetes, cardiovascular risk reduction in diabetes, chronic weight management, and adolescent obesity from age 12 ¹²³⁴.

A 3-year trial also delayed diabetes onset in prediabetes without that reaching the label ⁵. It is the oldest weight-indicated GLP-1: a long record, a daily injection, and smaller numbers than the weekly drugs ⁷.

How is Liraglutide used?

The label describes once-daily subcutaneous injection: 0.6 mg rising weekly to 3.0 mg for weight ⁹, 1.2 to 1.8 mg for diabetes ¹⁰. As reported in community threads, use mostly runs through prescription pens rather than research vials, following the same ladder. Descriptive only. Convention, not guidance.

How long does Liraglutide take to work?

Five weeks to full dose by label ⁹. SCALE measured its 8.4 kg loss at week 56 ¹, and the 3-year extension held near 6% down at week 160 ⁵. Appetite effects are reported within days of a step. The head-to-head ceiling is real: 6.4% vs semaglutide's 15.8% at 68 weeks ⁷.

Is Liraglutide an approved drug?

Yes, for specific indications. An approval attaches to a named indication, a named dose and a manufactured product. It does not extend to a research-market vial, an off-label goal, or a dose worked out on a forum.

On our index it is graded approved on clinical evidence and moderate on community adoption, and those two are rated separately on purpose.

Why choose Liraglutide over the weekly GLP-1s?

The record answers what it does, not what to choose. What it shows: a smaller weight effect head-to-head ⁷, and a daily rather than weekly injection ⁹.

It also has the class's longest post-market history, including LEADER's cardiovascular outcome win ³. Generics are now on the market. Where the weekly drugs are out of reach, that is the trade the record describes.

References

Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management [SCALE]. N Engl J Med. 2015. PMID 26132939
Garber A, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes [LEAD-3 Mono]. Lancet. 2009. PMID 18819705
Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [LEADER]. N Engl J Med. 2016. PMID 27295427
Kelly AS, et al. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020. PMID 32233338
le Roux CW, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes. Lancet. 2017. PMID 28237263
Armstrong MJ, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis [LEAN]. Lancet. 2016. PMID 26608256
Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022. PMID 35015037
Mathieu C, et al. Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016. PMID 27506222
Saxenda [liraglutide] Prescribing Information. Novo Nordisk. 2026. dailymed.nlm.nih.gov
Victoza [liraglutide] Prescribing Information. Novo Nordisk. 2023. dailymed.nlm.nih.gov

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.